SGMO News and Press, Sangamo Therapeutics Inc. From 02/22/23

- Sustained, elevated expression of alpha-galactosidase A (α-Gal A) activity observed in 13 patients for over two years for the longest treated patient as of cutoff date. - Achieved 78% globotriaosylceramide (Gb3) substrate clearance at 6-months and 77% reduction in urine...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to hold a conference call on Wednesday, February 22, 2023 at 4:30 p.m. ET to review its fourth quarter and full year 2022 financial results and business updates. Prior to the call,...

After a blistering start to the year, small-cap biotech stocks made a U-turn in the second week of February. Speaking to this point, shares of the optical genome mapping company Bionano Genomics (NASDAQ: BNGO) , the next-generation DNA sequencing company Pacific Biosciences of Californi...

Summary Sangamo's hemophilia A program is not convincing due to durability concerns. Fabry Disease program actually looks more promising. However, Fabry is in an early stage, and we won't see pivotal data for a while. I covered Sangamo ( SGMO ) thrice in the last three...

Sangamo Therapeutics, Inc. (SGMO) Q3 2022 Earnings Conference Call November 3, 2022 16:30 ET Company Participants Louise Wilkie - Investor Relations Sandy Macrae - Chief Executive Officer Nathalie Dubois-Stringfellow - Chief Development Officer Jason Fontenot...

Sangamo Therapeutics press release ( NASDAQ: SGMO ): Q3 GAAP EPS of -$0.34 beats by $0.02 . Revenue of $26.5M (-7.3% Y/Y) misses by $0.29M . On a GAAP basis, we expect our total operating expenses which includes non-cash stock-based compensation expenses, to ...

Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results. “This has been a year marked by progress ac...

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to release its third quarter 2022 financial results after the market closes on Thursday, November 3, 2022. The press release will be followed by a conference call at ...

- Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across four dose cohorts in the nine treated patients in the dose escalation phase. - All nine patients exhibited elevated α-Gal A activity, ranging from nearly 2-fold to 30-fold of mean no...

Summary Due to an extended downtrend in Athersys stock price due largely to a declining cash position, Athersys currently trades at a market cap near $24 million. The current valuation is miniscule when compared to valuations of other stem cell companies, especially when consideri...